Fig. 4From: The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosisEffects of PPAR agonist lanifibranor in SU5416-induced pulmonary hypertension in TβRII∆k-fib mice. A Right ventricular systolic pressure by treatment group (WT/TG with combined mean, vehicle, low-dose and high-dose lanifibranor). B Fulton index, RV/LV + S score by treatment group as aboveBack to article page